Literature DB >> 16434146

Essential hypertension seems to result from melatonin-induced epigenetic modifications in area postrema.

M K Irmak1, A Sizlan.   

Abstract

Essential hypertension is a complex multifactorial disorder with epigenetic and environmental factors contributing to its prevalence. Epigenetic system is a genetic regulatory mechanism that allows humans to maintain extraordinarily stable patterns of gene expression over many generations. Sympathetic nervous system plays a major role in the maintenance of hypertension and the rostral ventrolateral medulla is the main source of this sympathetic activation. A possible mechanism to explain the sympathetic hyperactivity in the rostral ventrolateral medulla is an action of the area postrema. Area postrema seems to be the region where a shift of the set-point to a higher operating pressure occurs resulting in hypertension. But, how can a shift occur in the area postrema. We propose that melatonin-induced epigenetic modifications in the neurons of area postrema plays a role in this shift. Area postrema is reported to contain high levels of melatonin receptors that play a role in the epigenetic modifications in certain cells. Environmental stressors cause epigenetic modifications in the neurons of area postrema via the pineal hormone melatonin and these changes lead to a shift in the set-point to a higher operating pressure. This signal is then sent via efferent projections to key medullary sympathetic nuclei in rostral ventrolateral medulla resulting in increases in sympathetic nerve activity. This model may explain the long-term alterations in sympathetic activity in essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434146     DOI: 10.1016/j.mehy.2005.10.016

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  12 in total

1.  Blood pressure changes in young male subjects exposed to a median altitude.

Authors:  Ali Sizlan; Recai Ogur; Mustafa Ozer; M Kemal Irmak
Journal:  Clin Auton Res       Date:  2008-04       Impact factor: 4.435

Review 2.  Hypertensive epigenetics: from DNA methylation to microRNAs.

Authors:  J Wang; L Gong; Y Tan; R Hui; Y Wang
Journal:  J Hum Hypertens       Date:  2015-01-29       Impact factor: 3.012

Review 3.  Role of epigenetics in pulmonary hypertension.

Authors:  Tara V Saco; Prasanna Tamarapu Parthasarathy; Young Cho; Richard F Lockey; Narasaiah Kolliputi
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-09       Impact factor: 4.249

Review 4.  Epigenetics and hypertension.

Authors:  Richard M Millis
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

Review 5.  Epigenetic mechanisms in heart development and disease.

Authors:  Shannalee R Martinez; Maresha S Gay; Lubo Zhang
Journal:  Drug Discov Today       Date:  2015-01-06       Impact factor: 7.851

6.  Gene expression profiling of cultured cells from brainstem of newborn spontaneously hypertensive and Wistar Kyoto rats.

Authors:  Merari F R Ferrari; Eduardo M Reis; João P P Matsumoto; Débora R Fior-Chadi
Journal:  Cell Mol Neurobiol       Date:  2008-10-24       Impact factor: 5.046

Review 7.  Epigenetic modification: a regulatory mechanism in essential hypertension.

Authors:  Mohammed Arif; Sakthivel Sadayappan; Richard C Becker; Lisa J Martin; Elaine M Urbina
Journal:  Hypertens Res       Date:  2019-03-13       Impact factor: 3.872

Review 8.  Melatonin, noncoding RNAs, messenger RNA stability and epigenetics--evidence, hints, gaps and perspectives.

Authors:  Rüdiger Hardeland
Journal:  Int J Mol Sci       Date:  2014-10-10       Impact factor: 5.923

Review 9.  Peripheral and central effects of melatonin on blood pressure regulation.

Authors:  Olga Pechanova; Ludovit Paulis; Fedor Simko
Journal:  Int J Mol Sci       Date:  2014-10-08       Impact factor: 5.923

10.  Melatonin modulates baroreflex control via area postrema.

Authors:  Luciana A Campos; Jose Cipolla-Neto; Lisete C Michelini
Journal:  Brain Behav       Date:  2013-02-17       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.